Decision-making on adjuvant radioactive iodine (RAI) treatment for early-stage papillary thyroid cancer (PTC) is complex because of uncertainties in medical evidence. Using a parallel, two-arm, randomized, controlled trial design, we examined the impact of a patient-directed computerized decision aid (DA) on the medical knowledge and decisional conflict in patients with early-stage PTC considering the choice of being treated with adjuvant RAI or not. The DA describes the rationale, possible risks and benefits, and the medical evidence uncertainty relating to the choice.
INTRODUCTION
Approximately 48,000 Americans 1 and 5,700 Canadians 2 were diagnosed with thyroid cancer in the past year. In Canada, the incidence of thyroid cancer is rising faster than any other malignancy, with a rise of 8.8% per year in women and 6.8% per year in men from 1998 to 2007.
2 Similar trends of increasing incidence of thyroid cancer have been observed in the United States, and almost half (48%) of new diagnoses are made in individuals younger than 45 years of age.
3 Most of the rise in incidence of new cases of thyroid cancer is accounted for by an increase in early-stage papillary thyroid carcinoma (PTC) 4 with the increased detection of small primary tumors (ie, 2 cm in diameter or smaller). 4, 5 In the United States, the 5-year survival rate for thyroid cancer is 97% for all stages and 100% for patients with disease localized to the thyroid 1 ; a similar overall survival rate of 98% has been reported in Canada. 1 As a consequence of the rise in incidence of thyroid cancer and the relatively low risk of dying of this disease, the number of thyroid cancer survivors is growing significantly in North America. Given the rising number of thyroid cancer survivors who are diagnosed at an early stage (ie, localized disease, which is associated with a low risk of disease-related mortality), careful consideration needs to be given to the potential long-term benefits and risks of cancer treatments, such as adjuvant radioactive iodine (RAI), in such patients.
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
For patients with early-stage PTC whose primary tumor is larger than 1 cm in diameter, the current expert recommendation is that most patients should undergo total thyroidectomy and that RAI treatment (also known as remnant ablation) be selectively considered. [6] [7] [8] There is considerable uncertainty in the evidence-based medical literature regarding the possible long-term benefit of adjuvant RAI treatment in reducing the risk of thyroid cancer-related recurrence in patients with early-stage PTC. 9 The uncertainty relating to adjuvant RAI treatment in early-stage PTC stems from the lack of long-term randomized controlled trials in this field and the conflicting findings of existing observational studies examining recurrence risk.
9 Despite these limitations, 9 RAI has been increasingly used in the treatment of thyroid cancer in the United States in recent decades. 10 For example, in Americans younger than age 45 years who have been diagnosed with early-stage, well-differentiated thyroid cancer, the rate of use of adjuvant RAI treatment has increased from 3.3% of patients in 1973 to 38.1% in 2006. 11 Although adjuvant RAI treatment is being increasingly used in thyroid cancer, 11 some patients may lack an awareness of the uncertainties related to treatment benefit and possible risks and may desire detailed supplemental information.
12 Decision aids (DAs) are instruments used to inform patients about available health care options, including evidence about potential treatment benefits and risks. 13 They may improve patients' medical knowledge, 14,15 increase active participation in medical decision making, 14 and reduce decisional conflict 14 compared with usual care. It is not known how a DA that explains medical evidence uncertainty related to a cancer treatment might have an impact on patients' medical knowledge and decisional conflict.
We recently developed and pilot-tested a patient-directed, computerized DA explaining the choice to accept or reject adjuvant RAI treatment for treatment of early-stage PTC. [16] [17] [18] It is intended to be used as an adjunct to individualized physician counseling, and it explains the following topics relating to adjuvant RAI treatment decision making for early-stage PTC: disease prognosis (disease-related mortality and recurrence risks), rationale for or against the treatment, potential benefits of the treatment (including the potential to facilitate disease surveillance and some conflicting evidence on the impact of recurrence risk), potential short-term adverse effects associated with the treatment (such as fatigue, nausea/vomiting, neck pain, salivary gland swelling/pain, taste changes, and dry mouth), potential long-term risks of the treatment (such as dry mouth, nasolacrimal duct obstruction, impact on menses, and the risk of second primary malignancies), uncertainty of relevant medical evidence on treatment benefit, disease follow-up implications, and reproductive considerations. [16] [17] [18] The data cited within the DA were based on a literature review, including some of our own published systematic reviews.
9,19-21 Within the DA, we explicitly reported the uncertainty of medical evidence related to the use of adjuvant RAI treatment for early-stage PTC, including an account of the lack of randomized controlled trials in the field and the limitations in interpreting the best available observational evidence.
Our primary objective in this randomized controlled trial was to evaluate the impact of this DA on medical knowledge of patients with early-stage PTC. Secondary objectives were to examine the impact of the DA on patients' decisional conflicts and the ultimate treatment choice.
PATIENTS AND METHODS

Trial Design
Consenting patients with early-stage PTC, for whom either accepting or declining adjuvant RAI treatment would be equally appropriate, were randomly assigned to a one-time exposure to a computerized DA (plus usual care) or to no exposure to a DA (with usual care), respectively. This parallel design randomized controlled trial was conducted in a single academic clinical center (Toronto General Hospital, University Health Network). The complete study protocol has been previously reported. 22 This trial was registered with ClinicalTrials.gov, and it was approved by the University Health Network Research Ethics Board. All participants provided written, informed consent.
Inclusion Criteria
Potentially eligible patients included individuals age 18 years or older who had complete surgical resection of their thyroid gland on or after Septem- ). Participants were required to be able to communicate in spoken and written English, use a computer, and provide informed consent.
Exclusion Criteria
Individuals concurrently diagnosed with any medullary, anaplastic, or poorly differentiated (or de-differentiated) thyroid cancer or thyroid lymphoma or those who had already received RAI treatment for thyroid cancer were not eligible for this study. Individuals who temporarily stopped taking thyroid hormone (for RAI treatment or testing) were not eligible to participate in the study while not being given the medication, because of the possibility that this could have a negative impact on cognitive abilities. Individuals whose thyroid cancer pathologic stage could not be confirmed were also ineligible.
Intervention
All participants received their usual care and counseling from their respective treating physicians before and after random assignment. In our region, usual care typically involves the care of a specialized head and neck surgeon (otolaryngologist or general surgeon with expertise in thyroid surgery) as well as one or more medical specialists (such as an endocrinologist, radiation oncologist, or nuclear medicine physician). All of the surgical and medical specialists are qualified under the Royal College of Physicians and Surgeons of Canada and participate in an annual maintenance of certification program. We had no restriction in our study on the types or number of physicians involved in patients' care. Participants in the intervention group self-navigated the DA Web site for up to a maximum of 60 minutes, on a personal desktop computer in a research office at the Toronto General Hospital. A research assistant supervised the study visit but was not allowed to navigate the DA or discuss medical content with the participant. To prevent contamination of the control group, no access to the DA Web site was permitted outside the study visit, and participants were not allowed to take home any materials that may have been printed from the Web site. Access to the DA Web site was password protected and only the study staff had access. No access to the DA was available to any physicians or patients outside the study during the trial. Participants were contacted by telephone approximately 6 to 12 months following random assignment to confirm their ultimate treatment choice.
Outcomes
The primary outcome of medical knowledge (measured by a questionnaire) was collected at the initial study visit, immediately after random assignment and exposure to the DA (in the intervention group), or without DA exposure (in the control group). The medical questionnaire was selfadministered and consisted of 10 true or false questions (scored by number of correct responses out of 10, with a maximal score of 10). 16, 17 The medical knowledge questionnaire encompassed the following topics: early-stage PTC prognosis (including questions related to mortality risk and possible recurrence), adjuvant RAI treatment preparation and treatment procedure, potential short-and long-term adverse effects of RAI treatment, medical follow-up implications (ie, impact on interpretation of thyroglobulin measurements), and uncertainty of medical evidence on the impact of RAI treatment on the risk of recurrence. 16, 17 A secondary outcome was decisional conflict 24, 25 relating to the decision to accept or reject adjuvant RAI treatment. Decisional conflict was measured by using the Decisional Conflict Scale (DCS), which is a 16-item, self-administered questionnaire in which total scores may range from 0 (no decisional conflict) to 100 (maximal decisional conflict). 24, 25 Participants were asked about their preference relating to RAI treatment choice at baseline (after random assignment but before exposure to the intervention) and after exposure to the intervention (or no intervention for controls), during the same study visit. The ultimate treatment decision was confirmed by telephone follow-up approximately 6 to 12 months following random assignment; at that time, participants were also asked who made the final treatment decision (ie, the patient, the doctor, shared decision between doctor and patient, or someone else).
Random Assignment, Allocation Concealment, Implementation, and Blinding
Central computerized randomization in a 1:1 ratio was performed at a patient level by using variable block sizes of 2 and 4 (allocation designed by a study statistician [K.E.T.]). After the participant signed informed consent for participation in the study, random assignment was performed by using the DA program, and the study allocation was then revealed to the participant. Immediately following random assignment, during the same study visit, intervention group participants were exposed to the DA (followed by testing), and the control group participants underwent testing (without DA exposure). Before the random assignment/testing visit, neither the participant, study staff, investigators, nor treating physicians were aware of the allocation, because it had not yet been assigned. There was no blinding of participants, study staff, or treating physicians after random assignment was completed. However, the statistician was blinded to the allocation of groups at the time of data analysis.
Statistical Methods and Sample Size Considerations
All analyses followed an intention-to-treat principle. For descriptive analyses, categorical data were expressed as number and percentage, whereas continuous data were expressed as mean and standard deviation (or range). Independent (Welsh's) two-sample t tests were used to compare questionnaire scores (expressed as continuous data) from medical knowledge and decisional conflict questionnaires in the intervention group compared with the control group. A Pearson's 2 analysis was used to perform a preplanned secondary analysis comparing the rate of RAI treatment use in each group at follow-up. The cutoff for statistical significance for all analyses was ␣ ϭ .05. Quantitative statistical analyses were performed by using PASW Statistics 18.0 (IBM, Chicago, IL) and R 2.12.0 (The R Foundation for Statistical Computing, Vienna, Austria 26 ). The sample size was calculated to detect a one-point difference in the mean score of the knowledge questionnaire between the intervention and usual care groups, assuming a standard deviation of 1.5 (Power and Precision software; Biostat, Englewood, NJ). The intended sample size was 37 individuals per group (total of 74; two-tailed ␣ ϭ .05; power 0.808).
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RESULTS
Participant Characteristics
The 74 study participants, including 62 women, were recruited between March 2010 and June 2011, and the study flow of participants is summarized in Figure 1 . The characteristics of study participants are provided in Table 1 . The mean time participants spent self-navigating the DA Web site was 30.1 minutes (standard Allocated to control group (n = 37) Received control intervention (n = 37) Did not receive control intervention (n = 0)
Excluded from analysis (n = 0)
Did not meet inclusion criteria (n = 22) Declined to participate (n = 11) Scheduling of study visit not (n = 3) possible because of timing 
Medical Knowledge, Decisional Conflict, and Treatment Choice
All data were complete, with no missing responses to questions. Medical knowledge about prognosis of early-stage PTC and adjuvant RAI treatment was significantly greater in the DA group (mean score, 9.7 of a maximum of 10; SD, 0.6; n ϭ 37) compared with the control group (mean score, 7.8 of 10; SD, 1.3; n ϭ 37; mean difference, 1.9; 95% CI, 1.4 to 2.3; P Ͻ .001). Decisional conflict relating to the decision to accept or reject adjuvant RAI treatment was significantly reduced in the DA group (mean score, 25.2 of a maximum score of 100; SD, 13.4; n ϭ 37) compared with the control group (mean score, 52.1; SD, 21.9; n ϭ 37; mean difference, 26.8; 95% CI, 18.4 to 35.3; P Ͻ .001). Furthermore, decisional conflict was reduced in all respective subscales of this tool in the DA group compared with the control group (respective P values Ͻ .001 for the Uncertainty Subscore, Informed Subscore, Values Clarity Subscore, Support Subscore, and Effective Decision Subscore). The treatment preferences of participants throughout the study and ultimate treatment choice are given in Table 2 . The rates of use of adjuvant RAI treatment were not significantly different between the two groups (decision aid group, 11 of 37 [29.7%]; controls, seven of 37 [18.9%]; 2 ϭ 1.175; df ϭ 1; P ϭ .278). The participants in the DA group identified the following individual(s) as primarily responsible for the ultimate treatment decision: the patient, 45.9% (17 of 27); the physician, 10.8% (four of 37); shared decision between the patient and the physician, 40.5% (15 of 37); or someone else, 2.7% (one of 37; a sibling with a history of PTC). The participants in the control group identified the following individual(s) as primarily responsible for the ultimate treatment decision: the patient, 24.3% (nine of 27); the physician, 24.3% (nine of 37); or shared decision between the patient and the physician, 51.4% (19 of 37).
DISCUSSION
In this randomized controlled trial, we have shown that a computerized DA that explains the choice of receiving or not receiving adjuvant RAI treatment improves medical knowledge and reduces decisional conflict of patients with early-stage PTC. However, exposure to the DA does not appear to have a significant impact on the ultimate RAI treatment choice. These findings are in keeping with recent systematic reviews of DAs in the medical literature, suggesting that DAs may improve patients' knowledge 14, 15 and reduce decisional conflict, 14 but they may have variable effects on the choice of medical treatment.
14, 15 We believe that DAs may be particularly valuable in facilitating decision making on complex interventions for which there is some evidence uncertainty. We believe that sharing information about evidence uncertainty relating to the choice of cancer treatment may result in more informed choices by patients and more realistic treatment expectations. This view is compatible with the recent Salzburg Statement on Shared Decision Making in which a call was made for clinicians to share important decision making with patients and provide accurate information about options and uncertainties tailored to individual patients' needs. 27 It is important to understand that although most patients want to have information relevant to a medical treatment choice, patients' individual preferences on the degree and nature of involvement in the final treatment decision may be highly variable, 28 and this may partly explain the heterogeneous effects of DAs on ultimate treatment choice. The strengths of this trial include the use of a randomized controlled design, review of surgical pathology reports (to ensure a homogenous thyroid cancer population), strict attention to avoiding external contamination of the control group (with no access permitted to the DA outside the study setting), and the completeness of data collection. Limitations of this study include a relatively small sample size, an uncertainty of the clinical significance of the measured differences in medical knowledge, a lack of measurement of thyroid hormone levels in study participants, a lack of data on the medical knowledge of treating physicians providing usual care, a lack of prospectively collected objective data on the interactions between study participants and their treating physicians (such as audio or video recordings of clinical discussions or measurements of clinical time used), and a lack of long-term outcome data on the effects of the DA (although collection of such data is planned in extended follow-up to our study). There are also several limitations that restrict the external generalizability of our results to other settings or populations, such as the performance of the study in one study center, the availability of the DA only in English, the relatively high education level and degree of computer experience of our study participants, the timing of the decision making (ie, a mean of a few months after thyroidectomy), and the exclusion of individuals who may have been withdrawn from thyroid hormone by their treating physicians at the time of decisionmaking. It is essential to highlight that our patient-directed DA is intended to be applied as an adjunct to physician counseling, for patients diagnosed with early-stage PTC who have had their thyroid completely surgically resected and in whom either accepting or declining adjuvant RAI treatment may be clinically reasonable. Advantages of a Web-based decision aid are that it may be reviewed at home by the patient at a time and pace that is best suited to the individual, it may be reviewed as needed, and the information can be shared with family members. It is important to note that more research is needed on potential physician-based knowledge translation interventions that may assist physicians in counseling patients with thyroid cancer with respect to RAI or other treatments.
In conclusion, a computerized patient-directed DA significantly improves medical knowledge and reduces decisional conflict in patients with early-stage PTC who are considering adjuvant RAI treatment. Our data also suggest that DAs may facilitate knowledge translation for decisions on cancer treatment that are subject to uncertainty of medical evidence. More research is needed to determine whether DAs that focus on other choices for cancer treatment subject to similar medical evidence uncertainty can improve the decisionmaking process and long-term health and psychosocial outcomes.
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The author(s) indicated no potential conflicts of interest. Abbreviation: RAI, radioactive iodine.
AUTHOR CONTRIBUTIONS
‫ء‬
The immediate post-intervention treatment preference was measured as part of the decisional conflict questionnaire, and participants were asked which of the following statements best described their opinion at the time, assuming they were offered the choice of receiving or not receiving RAI treatment: "I favor taking RAI treatment" or "I favor not taking RAI treatment." For participants in the decision aid group, the questionnaire was administered after exposure to the decision aid and the medical knowledge questionnaire on the same study visit. For participants in the control group, the questionnaire was administered without exposure to the decision aid but followed administration of the medical knowledge questionnaire on the same study visit. For the immediate post-intervention treatment preference question, participants were not offered an "I don't know" option.
†The final decision was ascertained at telephone follow-up with the participant at a mean of 6.3 months (standard deviation, 1.2 months) after initial random assignment.
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